Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers

ClinicalTrials.gov NCT03173742.

Saved in:
Bibliographic Details
Published inPLoS neglected tropical diseases Vol. 12; no. 1; p. e0006020
Main Authors Muñoz, Jose, Ballester, Maria Rosa, Antonijoan, Rosa Maria, Gich, Ignasi, Rodríguez, Montse, Colli, Enrico, Gold, Silvia, Krolewiecki, Alejandro J
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 01.01.2018
Public Library of Science (PLoS)
Subjects
Adipose tissue
Administració de medicaments
Administration of drugs
Anthelmintic agents
Antiparasitic agents
Avermectin
Bioavailability
Biology and Life Sciences
Body mass
Body mass index
Body size
Body weight
Dosage
Dosage and administration
Drug dosages
Drug therapy
Drugs
Farmacocinètica
Filariasis
Funding
Headache
Health aspects
Helminthiasis
High-performance liquid chromatography
Homology
Hospitals
HPLC
Ivermectin
Liquid chromatography
Malaria
Medical treatment
Medicine and Health Sciences
Onchocerca volvulus
Onchocerciasis
Parameters
Pharmacokinetics
Pharmacology
Research and Analysis Methods
Safety
Safety and security measures
Soil
Soil improvement
Soil treatment
Tissue
Transmission
Tropical climate
Tropical diseases
Uses
Vector-borne diseases
Weight
Youth volunteers
France
Argentina
Spain
Online AccessGet full text

Cover

More Information
Summary:ClinicalTrials.gov NCT03173742.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Yes. I have read the journal's policy and the authors of this manuscript have the following competing interests: EC and SG are members of Chemo Group, which includes Liconsa, the manufacturer of the study drug and Exeltis France, the funding source.
ISSN:1935-2735
1935-2727
1935-2735
DOI:10.1371/journal.pntd.0006020